Table 1.
CRISPR/Cas9 platforms | Advantages | Disadvantages | Non-viral vectors | Refs |
---|---|---|---|---|
Cas9 protein and sgRNA | swift onset transient duration low off-target effects | high cost endotoxin-contamination | Lipids CPP polymers DNA nanoclew Au nanoparticles zeolitic imidazole frameworks | 69,96–99,102,103,110,113,119 |
Cas9 mRNA and sgRNA | quick onset transient expression low off-target effects | poor stability | lipids zwitterionic amino-lipid nanoparticles | 104,105,112,116 |
CRISPR/Cas9 plasmid | low cost great stability | integration risk low efficiency delayed onset | lipids CPP polymers | 100,101,117,118 |